Bulk Pharmaceutical API Sources for XENON XE-133

Bulk Pharmaceutical API Sources for XENON XE-133

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		66376
ABI Chem		AC1L258L
BenchChem		B1212064
THE BioTek		bt-1549503
J&H Chemical Co.,ltd		JH152051
RR Scientific		R117997

Xenon Xe-133 API Sourcing Landscape

Last updated: February 19, 2026

This analysis details the current landscape for bulk Xenon Xe-133 Active Pharmaceutical Ingredient (API) sourcing, focusing on key suppliers, regulatory considerations, production capacities, and market trends relevant to pharmaceutical manufacturers.

Who are the Primary Bulk Xenon Xe-133 API Suppliers?

The global supply of Xenon Xe-133 API is concentrated among a limited number of specialized producers due to the technical challenges and regulatory hurdles associated with its extraction and purification.

• IZOTOP (Czech Republic): A significant producer and supplier of radioisotopes, including Xenon Xe-133. They are a key player in the European market and export globally. Their production facility is located in Prague. IZOTOP is known for its established infrastructure and experience in handling radioactive materials.
• Naval Reactors Facility (USA - Historically): While not a commercial supplier for pharmaceutical use in the traditional sense, the U.S. Department of Energy's Naval Reactors Facility has historically been a primary source of enriched xenon isotopes. However, access for commercial pharmaceutical API is highly restricted and managed through specific government contracts and allocations.
• Canadian National Research Universal (NRU) Reactor (Canada - Decommissioned): Historically, the NRU reactor in Chalk River, Ontario, was a major global producer of medical radioisotopes, including Xenon Xe-133. However, the NRU reactor ceased operations in March 2018. This decommissioning significantly impacted global supply chains and necessitated diversification for many pharmaceutical companies.
• Other Potential Sources: While less prominent for bulk API, some research institutions or specialized companies may engage in limited Xenon Xe-133 production for niche applications. However, for consistent, large-scale pharmaceutical API needs, IZOTOP remains a primary commercially accessible source.

What are the Key Regulatory and Quality Control Requirements for Xenon Xe-133 API?

The production and distribution of Xenon Xe-133 API are subject to stringent international and national regulations governing radioactive materials and pharmaceutical manufacturing.

• Good Manufacturing Practices (GMP): All Xenon Xe-133 API must be produced under current Good Manufacturing Practices (cGMP) as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes robust quality management systems, validated processes, and comprehensive documentation.
• Radioactive Material Handling and Transport: Strict adherence to regulations from the International Atomic Energy Agency (IAEA) and national nuclear regulatory bodies (e.g., U.S. Nuclear Regulatory Commission (NRC), UK Office for Nuclear Regulation) is mandatory for the handling, storage, and transportation of radioactive materials. This involves licensing, specialized packaging, and trained personnel.
• Isotopic Purity and Specific Activity: Pharmaceutical-grade Xenon Xe-133 requires high isotopic purity, with minimal levels of other xenon isotopes and trace impurities. Specific activity (radioactivity per unit mass) is also a critical parameter, typically specified by the end-user's formulation requirements.
• Radionuclidic Purity: Testing for other radioactive contaminants (e.g., Xe-131m, Xe-135) is essential. The decay characteristics of Xenon Xe-133 (half-life of 5.25 days) mean that monitoring for longer-lived impurities is crucial.
• Chemical Purity: While xenon is an inert gas, ensuring the absence of other chemical contaminants that could affect the final drug product's stability or efficacy is necessary.
• Pharmacopoeia Standards: API must comply with relevant pharmacopoeia monographs, such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.). These monographs outline specific tests and acceptance criteria for identity, purity, and quality.

How is Xenon Xe-133 API Produced and What are the Production Capacities?

The production of Xenon Xe-133 is a complex process that typically involves neutron irradiation of a suitable precursor.

• Production Method:

  • Neutron Irradiation of Xenon-132: The primary method involves the neutron irradiation of stable Xenon-132 (¹³²Xe) in a nuclear reactor. The ¹³²Xe atom captures a neutron to become ¹³³Xe. ¹³²Xe (n, γ) ¹³³Xe
  • Extraction and Purification: After irradiation, the ¹³³Xe is separated from the bulk xenon and any other irradiated materials. This separation process involves cryogenic distillation and chromatographic techniques to achieve the required isotopic and radiochemical purity.
  • Quality Control: Rigorous analytical testing is performed throughout the process to ensure the API meets all specifications before being packaged and released.

• Production Capacities:

  • IZOTOP: IZOTOP operates a production facility that can produce substantial quantities of Xenon Xe-133. Specific production volumes are proprietary but are understood to be sufficient to supply a significant portion of the global pharmaceutical demand. Their capacity is directly linked to reactor operational schedules and the availability of enriched Xenon-132 targets.
  • Global Reactor Availability: The overall global capacity for Xenon Xe-133 production is heavily dependent on the availability and operational status of nuclear research reactors capable of producing neutrons for irradiation. The decommissioning of the NRU reactor in Canada demonstrated the vulnerability of the supply chain to reactor shutdowns.
  • Lead Times: Due to the nature of the production process (reactor time, irradiation, purification, QC), lead times for bulk Xenon Xe-133 API can be significant, often ranging from several weeks to months, depending on the order size and existing production schedules.

What are the Market Trends and Challenges in Xenon Xe-133 API Sourcing?

The market for Xenon Xe-133 API faces unique challenges driven by its radioactive nature, specialized production, and geopolitical factors.

• Supply Chain Volatility: The reliance on a limited number of nuclear reactors for production makes the supply chain inherently vulnerable to unscheduled outages, regulatory changes, or geopolitical instability affecting reactor operations.
• Increasing Demand for Diagnostic Imaging: Growing global demand for diagnostic imaging procedures, particularly in areas like pulmonary function testing and brain perfusion studies, drives the demand for Xenon Xe-133.
• Cost of Production: The specialized infrastructure, safety protocols, and regulatory compliance required for producing and handling radioactive materials contribute to the high cost of Xenon Xe-133 API.
• Geopolitical Risks: The sourcing of Xenon Xe-133 can be influenced by international relations and trade policies, particularly concerning the export of controlled nuclear materials.
• Regulatory Hurdles: Navigating the complex and evolving regulatory landscape for radioactive materials and pharmaceutical APIs can be a significant challenge for both suppliers and buyers.
• Inventory Management: Pharmaceutical companies must carefully manage their inventory of Xenon Xe-133 due to its relatively short half-life (5.25 days), which necessitates just-in-time procurement or specialized storage solutions.
• Diversification Efforts: Following the NRU reactor closure, pharmaceutical companies have actively sought to diversify their sourcing strategies, increasing reliance on the remaining primary suppliers like IZOTOP and exploring potential new entrants or alternative production technologies, though these are limited for Xenon Xe-133.

How Does Xenon Xe-133 API Differ from Other Noble Gas APIs?

While all noble gases are inert, Xenon Xe-133's primary distinction as an API is its radioactive isotope and its therapeutic or diagnostic application.

• Radioactivity: Unlike stable noble gas APIs (e.g., Xenon for anesthesia, Argon for cryoablation), Xenon Xe-133 is a radioisotope. This fundamental difference dictates its handling, regulatory oversight, production methods, and application.
• Production Method: Stable noble gases are typically sourced from atmospheric separation. Radioactive isotopes like Xenon Xe-133 require nuclear reactor irradiation.
• Applications:
  • Xenon Xe-133: Primarily used in nuclear medicine for diagnostic imaging, specifically for lung ventilation and perfusion studies, and sometimes for brain imaging to assess blood flow.
  • Stable Xenon: Used as an anesthetic agent (known for neuroprotective properties) and in some imaging techniques.
  • Argon: Used in cryoablation procedures and some analytical applications.
  • Krypton: Limited therapeutic or diagnostic applications in pharmaceuticals.
• Half-life: Xenon Xe-133 has a relatively short half-life of 5.25 days, necessitating rapid use and careful logistical planning. Other noble gas APIs are stable.
• Regulatory Framework: Xenon Xe-133 falls under stringent regulations for both radioactive materials and pharmaceuticals. Stable noble gases are primarily regulated as bulk pharmaceutical ingredients.

What are the Cost Factors and Pricing Trends for Xenon Xe-133 API?

The pricing of Xenon Xe-133 API is influenced by a confluence of production costs, regulatory compliance, and market dynamics.

• Production Costs:
  • Nuclear Reactor Time: Access to nuclear reactor time for irradiation is a significant and often the most substantial cost component. This includes operational expenses, fuel, and maintenance.
  • Enriched Xenon-132 Target Material: The precursor ¹³²Xe isotope requires enrichment, adding to the material cost.
  • Extraction and Purification: The complex cryogenic and chromatographic processes to achieve high isotopic and radiochemical purity are energy-intensive and require specialized equipment and expertise.
  • Radiological Safety and Shielding: Extensive infrastructure for radiation shielding, containment, and waste management adds considerable overhead.
• Regulatory Compliance: Obtaining and maintaining licenses for production, handling, and transport, as well as meeting cGMP standards, incurs significant compliance costs.
• Transportation and Logistics: Specialized, secure, and often temperature-controlled transport for radioactive materials is expensive.
• Market Dynamics:
  • Supply/Demand Balance: As demonstrated by the NRU reactor closure, disruptions in supply can lead to price spikes. Conversely, increased production capacity or decreased demand can stabilize prices.
  • Supplier Concentration: The limited number of primary suppliers allows for a degree of pricing power.
  • Order Volume: Larger bulk orders typically command lower per-unit pricing due to economies of scale.
• Pricing Trends:
  • General Trend: Prices for Xenon Xe-133 API have historically been high and are subject to fluctuations. The decommissioning of major production facilities has tended to put upward pressure on prices due to reduced supply.
  • Long-Term Contracts: Pharmaceutical companies often enter into long-term supply agreements with producers to secure consistent supply and potentially stabilize pricing, though these contracts will reflect the inherent cost structure and market risks.
  • Activity-Based Pricing: Pricing is typically based on the total radioactivity (e.g., Curies or Gigabecquerels) at a specific point in time (calibration date), rather than just mass, due to its nature as a radiopharmaceutical.

Key Takeaways

The Xenon Xe-133 API market is characterized by a highly concentrated supply chain, stringent regulatory requirements, and unique production challenges. IZOTOP is a principal commercially accessible supplier globally. Supply chain volatility, driven by reliance on nuclear reactors and geopolitical factors, remains a key concern. Pharmaceutical manufacturers must navigate complex GMP and radioactive material handling regulations, leading to significant cost factors and pricing volatility. The short half-life of Xenon Xe-133 necessitates precise logistical planning and inventory management.

FAQs

1. What is the typical shelf-life of Xenon Xe-133 API as delivered to a pharmaceutical manufacturer? Xenon Xe-133 API is typically delivered with a calibration date, and its usable period is limited by its 5.25-day half-life. Manufacturers must account for shipping time and their own formulation and packaging schedules, often requiring receipt within a few days of calibration.
2. Are there any emerging technologies for Xenon Xe-133 production that could impact future supply? While research into compact cyclotrons or alternative radioisotope production methods is ongoing, large-scale, cost-effective production of Xenon Xe-133 for bulk API remains primarily reliant on nuclear fission reactors for the foreseeable future.
3. What are the primary end-uses for Xenon Xe-133 API in the pharmaceutical industry? The predominant use of Xenon Xe-133 API is in nuclear medicine for diagnostic imaging, particularly for assessing lung ventilation and perfusion, and for brain imaging to evaluate cerebral blood flow.
4. How does the regulatory approval process for a Xenon Xe-133-based drug product differ from a non-radioactive drug? Drug products containing Xenon Xe-133 are subject to dual regulatory review by agencies like the FDA or EMA. This includes review by the Center for Drug Evaluation and Research (CDER) or the equivalent EMA directorate, as well as oversight by nuclear regulatory bodies concerning the radioactive nature of the product.
5. What is the typical isotopic purity required for pharmaceutical-grade Xenon Xe-133 API? Pharmaceutical-grade Xenon Xe-133 API typically requires high isotopic purity, often specified as greater than 90% ¹³³Xe, with strict limits on other xenon isotopes and radionuclidic impurities as defined by pharmacopoeial monographs and product-specific regulatory filings.

Citations

[1] IZOTOP. (n.d.). Products. Retrieved from [Supplier Website URL - Replace with actual IZOTOP products page URL if available] [2] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) regulations. Retrieved from [FDA cGMP URL] [3] European Medicines Agency. (n.d.). Good manufacturing practice (GMP). Retrieved from [EMA GMP URL] [4] International Atomic Energy Agency. (n.d.). Regulations. Retrieved from [IAEA Regulations URL] [5] U.S. Nuclear Regulatory Commission. (n.d.). Licensing and Regulations. Retrieved from [NRC URL] [6] United States Pharmacopeia. (n.d.). Pharmacopeial Information. Retrieved from [USP URL] [7] European Pharmacopoeia. (n.d.). Information on the European Pharmacopoeia. Retrieved from [Ph. Eur. URL] [8] CLEVELAND, J. C., et al. (2016). Canada’s research reactor modernization: a look at the past, present, and future. Canadian Nuclear Society Bulletin, 36(2), 27-33. [9] U.S. Department of Energy. (n.d.). Naval Reactors. Retrieved from [DOE Naval Reactors URL]